We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Aug 2021 - 26 Aug 2021
Virtual Venue
29 Aug 2021 - 31 Aug 2021
Virtual Venue

Gestational Diabetes May Predict Autoimmune Diabetes Risk

By LabMedica International staff writers
Posted on 15 Jun 2021
Print article
Image: Women diagnosed with gestational diabetes are more likely to be autoantibody positive and develop type 1 diabetes in the decade after delivery compared with pregnant women without gestational diabetes (Photo courtesy of Kernodle Clinic)
Image: Women diagnosed with gestational diabetes are more likely to be autoantibody positive and develop type 1 diabetes in the decade after delivery compared with pregnant women without gestational diabetes (Photo courtesy of Kernodle Clinic)
Gestational diabetes is high blood sugar (glucose) that develops during pregnancy and usually disappears after giving birth. It can happen at any stage of pregnancy, but is more common in the second or third trimester.

Autoimmune diabetes, commonly referred to as type 1 diabetes mellitus (an older synonym is insulin-dependent diabetes mellitus), is a chronic immune-mediated disease characterized by insulin deficiency due to pancreatic islet beta-cell destruction with increasing blood glucose levels.

Medical Scientists at the Helsinki University Hospital (Helsinki, Finland) in a prospective cohort study, analyzed data from 391 women with gestational diabetes and 391 age-, parity- and delivery date-matched controls who delivered from 1984 through 1994 and underwent autoantibody testing during the first trimester of pregnancy. The team assessed levels of four autoantibodies associated with type 1 diabetes: Islet cell autoantibodies (ICA), glutamic acid decarboxylase autoantibodies (GADA), insulin autoantibodies (IAA) and insulinoma-associated antigen-2 autoantibodies (IA-2A). Women completed a follow-up questionnaire assessing later type 1 or type 2 diabetes diagnosis in 2012-2013. The mean follow-up time was 23 years.

The scientists observed single autoantibody positivity in 41(12%) of the gestational diabetes cohort and in eight (2.3%) of the control cohort. In the gestational diabetes cohort, nine (2.6%) tested positive for two autoantibodies and eight (2.3%) tested positive for three autoantibodies, whereas only one woman in the control cohort had two autoantibodies detected. Islet cell autoantibodies (ICA) positivity was found in 12.5% of cases, followed by GADA (6%), IA-2A (4.9%) and IAA (1.2%). In the control cohort, GADA positivity was found in 1.4% of cases, followed by IA-2A (0.8%), IAA (0.6%) and ICA (0.3%). All women with three positive autoantibodies developed type 1 diabetes within seven years from pregnancy with gestational diabetes. Development of type 2 diabetes and gestational diabetes occurred independent of autoantibody positivity.

Kaisu Luiro-Helve, MD, PhD, consultant in obstetrics and gynecology and reproductive endocrinology and senior author of the study, said, “If you are not the typical gestational diabetes candidate, but you have it, that may warrant more screening. Type 1 diabetes is not just a disease of the young. Type 1 usually occurs within 10 years of gestational diabetes, and that is the time when we need to stay alert and perhaps conduct another oral glucose tolerance test. Do not forget about these women after delivery.” The study was presented at the European Congress of Endocrinology virtual meeting held May 22-26, 2021.

Related Links:
Helsinki University Hospital

New
Gold Supplier
INFLUENZA A/B RAPID TEST
COMBO INFLUENZA A+B-CHECK-1
New
Gold Supplier
Proficiency Assessment Software
CellaVision Proficiency Software
New
Glucose & Lactate Measurement Analyzer
ecoTwenty
New
Quantitative SARS-CoV-2 Neutralizing Antibody ELISA
KTR-1036 EDI Quantitative SARS-CoV-2 Neutralizing Antibody ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: Primary angle closure glaucoma can cause permanent blindness if not treated quickly. A highly sensitive genetic test has been developed (Photo courtesy of Flinders University)

Highly Sensitive Genetic Test for Glaucoma Developed

In open-angle glaucoma, the angle in the eye where the iris meets the cornea is as wide and open as it should be, but the eye’s drainage canals become clogged over time, causing an increase in internal... Read more

Industry

view channel
Illustration

ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC

ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders. The acquisition will also provides the industry with a full range of osmometry solutions... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.